RT Journal Article
SR Electronic
A1 Parry, Nicola
T1 Anti-VEGF Agents: Changing the Treatment Landscape for Diabetic Retinopathy
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 19
SP 23
OP 24
DO 10.1177/155989771419016
UL http://mdc.sagepub.com/content/14/19/23.abstract
AB This article provides an update on some key trials conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net), including important contributions from Protocol I. This study showed that anti-vascular endothelial growth factor (VEGF) therapy as an initial strategy should be the gold standard of treatment for diabetic macular edema.